UY35823A - Profármacos de antagonista de nmda - Google Patents
Profármacos de antagonista de nmdaInfo
- Publication number
- UY35823A UY35823A UY0001035823A UY35823A UY35823A UY 35823 A UY35823 A UY 35823A UY 0001035823 A UY0001035823 A UY 0001035823A UY 35823 A UY35823 A UY 35823A UY 35823 A UY35823 A UY 35823A
- Authority
- UY
- Uruguay
- Prior art keywords
- propharms
- nmda antagonist
- nmda
- antagonist
- ethanamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899903P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35823A true UY35823A (es) | 2015-04-30 |
Family
ID=51947383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035823A UY35823A (es) | 2013-11-05 | 2014-11-05 | Profármacos de antagonista de nmda |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9822075B2 (enExample) |
| EP (3) | EP3066091B1 (enExample) |
| JP (4) | JP6479834B2 (enExample) |
| KR (2) | KR102336426B1 (enExample) |
| CN (2) | CN111187202B (enExample) |
| AR (1) | AR098319A1 (enExample) |
| AU (1) | AU2014345407B2 (enExample) |
| CA (1) | CA2928004C (enExample) |
| CY (1) | CY1121749T1 (enExample) |
| DK (1) | DK3066091T3 (enExample) |
| ES (3) | ES2733344T3 (enExample) |
| HR (2) | HRP20191159T1 (enExample) |
| HU (2) | HUE070532T2 (enExample) |
| LT (1) | LT3066091T (enExample) |
| MX (2) | MX394633B (enExample) |
| PL (2) | PL4001272T3 (enExample) |
| PT (1) | PT3066091T (enExample) |
| RS (2) | RS58991B1 (enExample) |
| RU (1) | RU2695372C2 (enExample) |
| SI (1) | SI3066091T1 (enExample) |
| SM (1) | SMT202500023T1 (enExample) |
| TR (1) | TR201909632T4 (enExample) |
| TW (1) | TW201609653A (enExample) |
| UY (1) | UY35823A (enExample) |
| WO (1) | WO2015067923A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102336426B1 (ko) | 2013-11-05 | 2021-12-08 | 아스트라제네카 아베 | Nmda 길항제 전구약물 |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| CN107578281B (zh) * | 2017-08-31 | 2021-03-30 | 湖南大学 | 电子商务环境下用户优惠券行为预测方法及模型构建方法 |
| BR112022025900A2 (pt) | 2020-06-23 | 2023-01-10 | Biohaven Therapeutics Ltd | Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina |
| CN122421958A (zh) * | 2023-12-22 | 2026-07-17 | 拜奥海芬治疗学有限公司 | 神经性障碍的组合治疗 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7909514L (sv) * | 1979-11-16 | 1981-05-17 | Astra Laekemedel Ab | Nya halofenyl-pyridyl-allylaminderivat |
| US4769466A (en) | 1987-02-06 | 1988-09-06 | Pennwalt Corporation | 2-aminoacetamide pyridinyl derivatives |
| ES2083972T3 (es) * | 1988-08-12 | 1996-05-01 | Astra Ab | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. |
| ES2142320T3 (es) | 1991-10-30 | 2000-04-16 | Astra Ab | Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos. |
| NZ251384A (en) * | 1992-04-03 | 1996-10-28 | Fisons Corp | (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| PA8525601A1 (es) | 2000-08-21 | 2002-04-25 | Hoffmann La Roche | Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol |
| AU2002310409C1 (en) | 2001-06-11 | 2008-04-17 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
| GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| CA2551859C (en) | 2003-12-30 | 2011-10-04 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| EP1929030A2 (en) * | 2005-09-08 | 2008-06-11 | Shire LLC | Prodrugs of t3 and t4 with enhanced bioavailability |
| CN101246417B (zh) | 2007-02-13 | 2010-09-29 | 艾威梯科技(北京)有限公司 | 音频数据流输入/输出无间断软件切换的方法和系统 |
| CA2710538A1 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| US9062094B2 (en) * | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| US8580850B2 (en) * | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
| KR102336426B1 (ko) | 2013-11-05 | 2021-12-08 | 아스트라제네카 아베 | Nmda 길항제 전구약물 |
-
2014
- 2014-10-30 KR KR1020167014625A patent/KR102336426B1/ko active Active
- 2014-10-30 TR TR2019/09632T patent/TR201909632T4/tr unknown
- 2014-10-30 HU HUE21196371A patent/HUE070532T2/hu unknown
- 2014-10-30 PT PT14802476T patent/PT3066091T/pt unknown
- 2014-10-30 AU AU2014345407A patent/AU2014345407B2/en active Active
- 2014-10-30 HR HRP20191159TT patent/HRP20191159T1/hr unknown
- 2014-10-30 PL PL21196371.5T patent/PL4001272T3/pl unknown
- 2014-10-30 CA CA2928004A patent/CA2928004C/en active Active
- 2014-10-30 US US15/034,727 patent/US9822075B2/en active Active
- 2014-10-30 HR HRP20241784TT patent/HRP20241784T1/hr unknown
- 2014-10-30 RS RS20190821A patent/RS58991B1/sr unknown
- 2014-10-30 LT LTEP14802476.3T patent/LT3066091T/lt unknown
- 2014-10-30 PL PL14802476T patent/PL3066091T3/pl unknown
- 2014-10-30 MX MX2020011946A patent/MX394633B/es unknown
- 2014-10-30 DK DK14802476.3T patent/DK3066091T3/da active
- 2014-10-30 CN CN202010014023.3A patent/CN111187202B/zh active Active
- 2014-10-30 RS RS20241459A patent/RS66369B1/sr unknown
- 2014-10-30 MX MX2016005567A patent/MX377276B/es active IP Right Grant
- 2014-10-30 HU HUE14802476A patent/HUE045001T2/hu unknown
- 2014-10-30 EP EP14802476.3A patent/EP3066091B1/en active Active
- 2014-10-30 JP JP2016551069A patent/JP6479834B2/ja active Active
- 2014-10-30 ES ES14802476T patent/ES2733344T3/es active Active
- 2014-10-30 KR KR1020217039470A patent/KR102469167B1/ko active Active
- 2014-10-30 EP EP19166031.5A patent/EP3564234B1/en active Active
- 2014-10-30 RU RU2016119493A patent/RU2695372C2/ru active
- 2014-10-30 ES ES19166031T patent/ES2894903T3/es active Active
- 2014-10-30 WO PCT/GB2014/053236 patent/WO2015067923A1/en not_active Ceased
- 2014-10-30 SI SI201431242T patent/SI3066091T1/sl unknown
- 2014-10-30 SM SM20250023T patent/SMT202500023T1/it unknown
- 2014-10-30 EP EP21196371.5A patent/EP4001272B1/en active Active
- 2014-10-30 ES ES21196371T patent/ES2999064T3/es active Active
- 2014-10-30 CN CN201480060416.0A patent/CN105683180B/zh active Active
- 2014-11-05 TW TW103138423A patent/TW201609653A/zh unknown
- 2014-11-05 AR ARP140104166A patent/AR098319A1/es unknown
- 2014-11-05 UY UY0001035823A patent/UY35823A/es not_active Application Discontinuation
-
2017
- 2017-10-17 US US15/785,654 patent/US10207994B2/en active Active
-
2019
- 2019-01-20 US US16/252,648 patent/US10815199B2/en active Active
- 2019-02-05 JP JP2019018440A patent/JP6633233B2/ja active Active
- 2019-07-02 CY CY20191100691T patent/CY1121749T1/el unknown
- 2019-12-10 JP JP2019222567A patent/JP6856737B2/ja active Active
-
2020
- 2020-10-26 US US17/079,553 patent/US12516023B2/en active Active
-
2021
- 2021-03-18 JP JP2021044193A patent/JP7234278B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| UY35499A (es) | Indazoles sustituidos con diaminoheteroarilo | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CL2016000038A1 (es) | Piraxolo-piridinaminas sustituidas | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| CL2017001615A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211215 |